Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ZNTL
Zentalis Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close
Mar 3, 2026 3:59:59 PM EST
2.38USD-5.000%(-0.12)390,890
2.37Bid   2.39Ask   0.02Spread
Pre-market
Feb 27, 2026 9:04:30 AM EST
2.51USD+0.400%(+0.01)0
After-hours
Mar 3, 2026 4:00:30 PM EST
2.38USD+0.211%(0.00)603
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 17, 2021
07:22AM EST  10 Biggest Price Target Changes For Friday   Benzinga
04:41AM EST  SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Raises Price Target to $97   Benzinga
Dec 2, 2021
07:00AM EST  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is hosting a virtual R&D Day on December 16, 2021 from 11:00 a.m. to 12:00 p.m. EST. Additional details on the event are summarized below.   GlobeNewswire Inc
Nov 17, 2021
07:31AM EST  Zentalis Pharma Announces Fast Track Designation Granted By FDA To ZN-c3 For Uterine Serous Carcinoma   RTTNews
07:06AM EST  Zentalis Pharmaceuticals Announces Fast Track Designation Granted By FDA To ZN-c3 For The Treatment Of Uterine Serous Carcinoma   Benzinga
07:00AM EST  Zentalis Pharmaceuticals Announces Fast Track Designation Granted   GlobeNewswire Inc
Nov 11, 2021
06:38AM EST  06:38 Thursday, November 11, 2021Wedbush (RTTNews) - Wedbush Reiterates Zentalis Pharmaceuticals, LLC (ZNTL) At Outperform With $89 Price Target   RTTNews
06:17AM EST  HC Wainwright & Co. Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $120   Benzinga
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
07:27AM EST  Zentalis Pharmaceuticals Q3 EPS $(0.09) Up From $(0.91) YoY   Benzinga
07:00AM EST  Initiated a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma   GlobeNewswire Inc
Nov 9, 2021
07:00AM EST  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will present at two upcoming investor conferences.   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Sep 30, 2021
11:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021   Benzinga
04:53AM EDT  Stifel Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $84   Benzinga
Sep 29, 2021
10:12AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021   Benzinga
04:48AM EDT  Oppenheimer Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $90   Benzinga
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 13, 2021
07:03AM EDT  Zentalis Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Study Of ZN-c3 In Combination With Gemcitabine In Patients With Osteosarcoma   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals Announces First Patient Dosed in the   GlobeNewswire Inc
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals to Present at the European Society for   GlobeNewswire Inc
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
07:03AM EDT  Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the publication of the discovery of ZN-c3, the Companys highly potent and selective WEE1 inhibitor candidate, in the Journal of Medicinal Chemistry.   GlobeNewswire Inc
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 12, 2021
07:28AM EDT  Zentalis Pharmaceuticals Q2 EPS $1.34 Up From $(0.78) YoY   Benzinga
07:00AM EDT  Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles   GlobeNewswire Inc
Aug 4, 2021
07:00AM EDT  Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow   GlobeNewswire Inc
Aug 2, 2021
07:31AM EDT  Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma   Benzinga
07:30AM EDT  Zentalis Pharmaceuticals Announces First Patient Dosed in   GlobeNewswire Inc
07:00AM EDT  Zentera Therapeutics Announces Closing of $75 Million Series B   GlobeNewswire Inc
Jul 1, 2021
04:01PM EDT  Zentalis Pharmaceuticals Announces Closing of Offering of Common   GlobeNewswire Inc
Jun 29, 2021
11:41AM EDT  Shares of clinical-stage biopharmaceutical company Zentalis Pharmaceuticals, Inc. (ZNTL) are rising 10 percent on Tuesday's trading after the company priced its public offering of 3.1 million shares at $48.50 per share. The offering will raise about $150.4 million in proceeds. The public offering will close on July 1.   RTTNews
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
06:54AM EDT  Zentalis Secures $150M In Equity Funding   Benzinga
Jun 28, 2021
09:09PM EDT  Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock   GlobeNewswire Inc
04:19PM EDT  Zentalis Pharmaceuticals Announces $150M Common Stock Offering   Benzinga
04:18PM EDT  Zentalis Pharmaceuticals Announces Proposed Public Offering of   GlobeNewswire Inc
07:06AM EDT  Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On ZN-c3 And ZN-c5 And Two Potentially Registrational Trials For ZN-c3, With The First Trial Already Initiated   Benzinga
07:00AM EDT  Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an additional unconfirmed PR in USC   GlobeNewswire Inc
Jun 21, 2021
09:15AM EDT  Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.   GlobeNewswire Inc
May 28, 2021
07:00AM EDT  Zentalis Pharmaceuticals to Participate in the Jefferies Virtual   GlobeNewswire Inc
May 21, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021   Benzinga
06:37AM EDT  UBS Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $91   Benzinga
May 19, 2021
08:00AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:20AM EDT  HC Wainwright & Co. Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $80   Benzinga
May 17, 2021
07:23AM EDT  Zentalis Pharmaceuticals Q1 EPS $(1.24) Up From $(2.88) YoY   Benzinga
07:00AM EDT  Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily pre-treated patients   GlobeNewswire Inc
May 4, 2021
06:28AM EDT  Zentalis Pharmaceuticals Inc Files for Up to $200M Mixed Shelf   Benzinga
Apr 28, 2021
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
Apr 27, 2021
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
Apr 20, 2021
08:07AM EDT  Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement With Zentalis Pharmaceuticals; Financial Details Not Disclosed   Benzinga
08:00AM EDT  Collaboration to use Gains proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) computational platform technology to identify new and previouslydifficult-to-drug oncology targets   GlobeNewswire Inc
Apr 13, 2021
08:33AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:22AM EDT  SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Raises Price Target to $64   Benzinga
Apr 12, 2021
11:18AM EDT  Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials   Benzinga
08:43AM EDT  Zentalis Enters Clinical Collaboration And Supply   RTTNews
07:06AM EDT  Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals Enters into Clinical Collaboration and   GlobeNewswire Inc
Apr 10, 2021
01:30PM EDT  ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors   GlobeNewswire Inc
Mar 26, 2021
07:38AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
06:13AM EDT  HC Wainwright & Co. Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $65   Benzinga
Mar 25, 2021
07:07AM EDT  Zentalis Pharmaceuticals Reports Q4 Net Loss Of $40.04M Compared To $14.5M YoY   Benzinga
07:00AM EDT  Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5   GlobeNewswire Inc
Mar 10, 2021
04:37PM EST  Zentalis Pharma Reports Will Present Late-Breaker Oral Presentation At American Association For Cancer Research Apr. 10   Benzinga
04:30PM EST  Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation   GlobeNewswire Inc
Feb 25, 2021
07:34AM EST  Zentalis Pharmaceuticals, Tempus Announce Strategic Collaboration To Advance R&D Capabilities   Benzinga
07:00AM EST  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced a strategic collaboration with Tempus to leverage the companys patient-derived organoid biological modeling platform to strengthen Zentalis discovery and research capabilities.   GlobeNewswire Inc
Feb 24, 2021
07:03AM EST  Zentalis Pharmaceuticals Says To Present Initial Clinical Data On ZN-c3 At AACR Annual Meeting 2021   Benzinga
07:00AM EST  Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3   GlobeNewswire Inc
Feb 10, 2021
07:00AM EST  Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch   GlobeNewswire Inc
Feb 5, 2021
07:00AM EST  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.   GlobeNewswire Inc
Jan 20, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2021   Benzinga
05:31AM EST  Wedbush Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $65   Benzinga
Jan 6, 2021
07:27AM EST  Zentalis Pharmaceuticals Announces the Initiation Of Multiple Early-Stage Clinical Trials   Benzinga
07:00AM EST  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis has initiated patient dosing in three new combination and monotherapy clinical trials:   GlobeNewswire Inc
Dec 16, 2020
01:21PM EST  Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Raises Price Target to $75   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Nov 12, 2020
07:00AM EST  Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
Nov 11, 2020
08:28AM EST  Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Raises Price Target to $50   Benzinga
Nov 9, 2020
07:22AM EST  Zentalis Pharmaceuticals Q3 EPS $(0.91)   Benzinga
07:00AM EST  Announced topline data from thePhase 1 monotherapy dose escalation trial of ZN-c5, its investigational oral SERD, in patients with ER+/HER2- advanced breast cancer; Phase 2 trial expected to initiate in H1 2021   GlobeNewswire Inc
Sep 29, 2020
06:01AM EDT  Cantor Fitzgerald Initiates Coverage On Zentalis Pharmaceuticals with Overweight Rating, Announces Price Target of $44   Benzinga
Sep 11, 2020
07:00AM EDT  Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual   GlobeNewswire Inc
Sep 1, 2020
07:21AM EDT  Zentalis Appoints Alexis Pinto As Chief Legal Officer   RTTNews
07:00AM EDT  Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer   GlobeNewswire Inc
Aug 27, 2020
06:07AM EDT  HC Wainwright & Co. Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $43   Benzinga
Aug 24, 2020
08:19AM EDT  Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Raises Price Target to $49   Benzinga
Aug 13, 2020
07:17AM EDT  Zentalis Pharmaceuticals Q2 EPS $(0.78)   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial   GlobeNewswire Inc
Jul 27, 2020
04:21PM EDT  Zentalis Pharmaceuticals Announces 3.75M Share Proposed Public Offering Of Common Stock   Benzinga
04:19PM EDT  Zentalis Pharmaceuticals Announces Proposed Public Offering of   GlobeNewswire Inc
07:51AM EDT  Zentalis Announces Clinical Collaboration Agreement With Eli Lilly   RTTNews
07:13AM EDT  Zentalis Pharmaceuticals Enters Into Clinical Collaboration With Eli Lilly & Co. To Evaluate Its Oral SERD ZN-c5 In Combination With Abemaciclib   Benzinga
07:00AM EDT  Zentalis Pharmaceuticals Enters into Clinical Collaboration with   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC